Avramis VI - Search Results

1

Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.

Albertsen BK, Schrøder H, Jakobsen P, Avramis VI, Müller HJ, Schmiegelow K, Carlsen NT. Albertsen BK, et al. Among authors: avramis vi. Med Pediatr Oncol. 2002 May;38(5):310-6. doi: 10.1002/mpo.10096. Med Pediatr Oncol. 2002. PMID: 11979454

2

Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system.

Albertsen BK, Schrøder H, Ingerslev J, Jakobsen P, Avramis VI, Müller HJ, Carlsen NT, Schmiegelow K. Albertsen BK, et al. Among authors: avramis vi. Br J Haematol. 2001 Dec;115(4):983-90. doi: 10.1046/j.1365-2141.2001.03148.x. Br J Haematol. 2001. PMID: 11843837 Free article.

3

Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.

Klug Albertsen B, Schmiegelow K, Schrøder H, Carlsen NT, Rosthøj S, Avramis VI, Jakobsen P. Klug Albertsen B, et al. Among authors: avramis vi. Cancer Chemother Pharmacol. 2002 Aug;50(2):117-20. doi: 10.1007/s00280-002-0466-y. Epub 2002 Jun 15. Cancer Chemother Pharmacol. 2002. PMID: 12172975

4

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE, Avramis VI; Children's Cancer Group Study CCG-1961. Panosyan EH, et al. Among authors: avramis ia, avramis vi. J Pediatr Hematol Oncol. 2004 Apr;26(4):217-26. doi: 10.1097/00043426-200404000-00002. J Pediatr Hematol Oncol. 2004. PMID: 15087948 Clinical Trial.

5

Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.

Avramis VI, Spence SA. Avramis VI, et al. J Pediatr Hematol Oncol. 2007 Apr;29(4):239-47. doi: 10.1097/MPH.0b013e318047b79d. J Pediatr Hematol Oncol. 2007. PMID: 17414566

6

Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).

Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI. Jarrar M, et al. Among authors: avramis vi. Pediatr Blood Cancer. 2006 Aug;47(2):141-6. doi: 10.1002/pbc.20713. Pediatr Blood Cancer. 2006. PMID: 16425271

7

Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.

Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL. Avramis VI, et al. Among authors: avramis ev. Anticancer Res. 2007 Jul-Aug;27(4C):2561-72. Anticancer Res. 2007. PMID: 17695416 Free article.

8

Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.

Ozkaynak MF, Avramis VI, Carcich S, Ortega JA. Ozkaynak MF, et al. Among authors: avramis vi. Med Pediatr Oncol. 1998 Dec;31(6):475-82. doi: 10.1002/(sici)1096-911x(199812)31:6<475::aid-mpo3>3.0.co;2-7. Med Pediatr Oncol. 1998. PMID: 9835899

9

Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.

Hawkins DS, Park JR, Thomson BG, Felgenhauer JL, Holcenberg JS, Panosyan EH, Avramis VI. Hawkins DS, et al. Among authors: avramis vi. Clin Cancer Res. 2004 Aug 15;10(16):5335-41. doi: 10.1158/1078-0432.CCR-04-0222. Clin Cancer Res. 2004. PMID: 15328169

10

Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.

Avramis VI, Panosyan EH. Avramis VI, et al. Clin Pharmacokinet. 2005;44(4):367-93. doi: 10.2165/00003088-200544040-00003. Clin Pharmacokinet. 2005. PMID: 15828851 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

73 results

Search Page